| Name | Title | Contact Details |
|---|
Virtual Radiologic (vRad) is a technology-enabled national radiology practice working in partnership with local radiologists and hospitals to optimize radiology’s pivotal role in patient care. vRad’s more than 400 radiologists serve 2,000+ facilities, reading 7 million studies annually. Delivering access to extensive subspecialty coverage, vRad contributes to improved quality of patient care. And with its next-generation technology, vRad enhances productivity, helping to lower the overall cost of care while expediting time to accurate diagnosis and treatment.
Allyis Inc is a Bellevue, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oxford Nanopore Technologies aims to disrupt the paradigm of biological analysis. Our technology and commercial model has already opened up DNA analysis to researchers who previously had no direct access to sequencing technologies, freeing them up to perform analyses in their own labs, in real time or in the field. Over time, the technology will continue to improve, new form factors of the technology will be introduced and workflows will be further simplified by new preparation techniques or analysis workflows. This technology pathway is designed to enable the analysis of any living thing, by any person, in any environment. Oxford Nanopore has developed the worlds first and only nanopore DNA sequencer, the MinION. The MinION is a portable, real time, long-read, low cost device that has been designed to bring easy biological analyses to anyone, whether in scientific research, education or a range of real world applications such as disease/pathogen surveillance, environmental monitoring, food chain surveillance, self-quantification or even microgravity biology. Commercially available since 2015, the MinION is in use by a thriving community of scientists in >50 countries, where it is enabling myriad applications within the traditional laboratory environment and in the field. Nanopore sensing technology is fully scalable. The GridION X5 is a desktop device that includes compute module and the ability to run up to five MinION Flow Cells. The the high-throughput/sample number PromethION is currently being released in the PromethION Early Access Programme (PEAP). Oxford Nanopore is focused on making DNA based analyses easy enough for any user and so we are working to simplify the sample preparation and data analysis processes. For sample preparation this includes a 5-10 minute sample prep kit, and VolTRAX (in development), a rapid, programmable, portable, disposable sample preparation device designed to prepare DNA for addition to a nanopore sequencing device.
Regado Biosciences, Inc., is a biopharmaceutical company focused on the discovery and development of novel, oligonucleotide-based actively controllable therapeutics. Our initial focus is on applications in the acute and sub-acute cardiovascular therapeutic area. The company's lead product candidate, REG1, is a two-component system consisting of pegnivacogin, an anticoagulant aptamer specifically targeting coagulation Factor IXa, and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial, a worldwide Phase 3 trial enrolling 13,200 patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI), a hospital-based procedure used to mechanically open or widen obstructed coronary arteries. Regado's actively controllable product candidates have the potential to improve patient outcomes and enhance the patient experience, provide direct therapeutic control to physicians and reduce overall treatment costs.
Just. is an integrated design company focused on the technology of biotherapeutics, from molecule to manufacturing plant. We believe that technological innovation will accelerate biotherapeutic development and dramatically reduce the cost of these vital medicines.